Hartwig Medical Foundation
To make the right treatment decision, cancer specialists need to collect all the available diagnostic information from the patient and their tumor.
We are contributing to this work by:
Developing
innovative molecular tests, for identifying the characteristics of the tumor.
Collecting and storing
knowledge of and information about the patient and their tumor.
Integrating
the information and knowledge with treatment outcome to accelerate scientific research. This enables us to learn from the data of today’s patients and provide better treatment for the patients of tomorrow.
Share your data
Your contribution to improving the treatment of tomorrow’s patients is important. Share your data, too!
Read moreShare your data and share our vision for the future of cancer diagnosis
Read the latest news
Whole genome sequencing: the future of molecular diagnostics in gynecological cancer?
To mark Gynecological Oncology Awareness Month, we spoke with oncologist Eelke Gort about the role of molecular diagnostics in these …
GLOW Study Ends – But WGS Remains Valuable for Glioblastoma Patients
As of October 1, 2025, the GLOW study will officially come to an end. Interim analysis has shown growing enthusiasm …
Hartwig Medical Foundation welcomes new managing director
Hartwig Medical Foundation is pleased to announce that Robert Jan Lamers has joined the organization as its new managing director, …
Dutch Healthcare Institute approves reimbursement of whole genome sequencing (WGS) for targeted cancer treatment
The Dutch National Health Care Institute (Zorginstituut Nederland, ZiNL) has approved the reimbursement of whole genome sequencing (WGS) through the …
Without structured real world data, it remains guesswork who truly benefits
The decision by the Dutch National Health Care Institute (Zorginstituut Nederland, ZiNL) to reassess the reimbursement of expensive medicines after …
Update on the GENAYA Project: DNA from 500 Young Cancer Patients Analyzed
Should young people with cancer receive different treatment than older patients? We suspect they do, but there’s currently not enough …
Read the latest blogs
Medicines Policy must be based on real world data
The recent decision by the National Health Care Institute to re-evaluate expensive cancer medicines in real-world practice is a logical …
Read more
Cancer, a rare disease?
It may come as a surprise to many on this International Rare Disease Day (February 28), that a significant number …
Read more
The big advantage of having Hartwig Medical Foundation data available in the cloud
I don’t remember exactly when I first heard about Hartwig Medical Foundation and the whole genome sequencing data it has …
Read more
It is important to unravel the DNA in rare types of cancer; 21% of patients with cancer have a rare form.